Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001-Reference-Cited by-同舟云学术

Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001

Published:2021-12-13 Issue:24 Volume:64 Page:18193-18208
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Nagy Mark A.¹,Hilgraf Robert¹,Mortensen Deborah S.¹^ORCID,Elsner Jan¹^ORCID,Norris Stephen¹,Tikhe Jayashree¹,Yoon Won¹,Paisner David¹,Delgado Mercedes¹,Erdman Paul¹,Haelewyn Jason¹,Khambatta Godrej¹,Xu Li¹,Romanow William J.¹,Condroski Kevin¹^ORCID,Bahmanyar Sogole¹,McCarrick Meg¹,Benish Brent¹,Blease Kate¹,LeBrun Laurie¹,Moghaddam Mehran F.¹,Apuy Julius¹,Canan Stacie S.¹,Bennett Brydon L.¹,Satoh Yoshitaka¹

Affiliation:

1. Bristol Myers Squibb, 10300 Campus Point Drive, Suite 100, San Diego, California 92121, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c01716

Reference23 articles.

1. Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets

2. Idiopathic Pulmonary Fibrosis: A Review of Disease, Pharmacological, and Nonpharmacological Strategies With a Focus on Symptoms, Function, and Health-Related Quality of Life

3. The functional contrariety of JNK

4. JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting JNK kinase inhibitors via molecular docking: A promising strategy to address tumorigenesis and drug resistance;Bioorganic Chemistry;2024-12

2. Update on JNK inhibitor patents: 2015 to present;Expert Opinion on Therapeutic Patents;2024-09-08

3. Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis;American Journal of Respiratory and Critical Care Medicine;2024-08-15

4. “A Mighty Flame Can Follow a Tiny Spark”: Is This the Case of c-Jun N-Terminal Kinase 1 Inhibitors in Idiopathic Pulmonary Fibrosis?;American Journal of Respiratory and Critical Care Medicine;2024-08-15

5. Evaluation of novel pyrazol-4-yl pyridine derivatives possessing arylsulfonamide tethers as c-Jun N-terminal kinase (JNK) inhibitors in leukemia cells;European Journal of Medicinal Chemistry;2023-12